EP Patent

EP2366378A1 — Sustained-release donepezil formulations

Assigned to Dexcel Pharma Technologies Ltd · Expires 2011-09-21 · 15y expired

What this patent protects

A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.

USPTO Abstract

A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.

Drugs covered by this patent

Patent Metadata

Patent number
EP2366378A1
Jurisdiction
EP
Classification
—
Expires
2011-09-21
Drug substance claim
No
Drug product claim
No
Assignee
Dexcel Pharma Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.